Hepatocellular adenoma (patient information)
For the WikiDoc page on this topic, click here
Hepatocellular adenoma |
Hepatocellular adenoma On the Web |
---|
Risk calculators and risk factors for Hepatocellular adenoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]
Overview
What are the symptoms of Hepatocellular adenoma?
Small hepatocellular adenomas are generally asymptomatic.
- Abdominal pain is the most common presenting symptom in some patients, and the pain is usually related to tumoral hemorrhage.
- Right upper quadrant abdominal fullness or discomfort is present in 40% of cases due to mass effect.
- Eventually, spontaneous rupture or hemorrhage may occur, leading to acute abdominal pain with progression to hypotension and even death.
- Patients with hepatocellular adenomas typically have a history of oral contraceptive use (females) and long term anabolic steroids use (males).
What causes Hepatocellular adenoma?
- The causes of hepatocellular adenoma include;
- Oral contraceptive medications
- The causal relationship is proportional to the hormonal dose and duration of medication, highest in women over 30 years of age and after 24 months of using oral contraceptives.
- Pregnancy
- Glycogen storage disease types I,II and IV
- Long term use of anabolic androgenic steroids
- Metabolic syndrome
- Maturity onset diabetes of young (MODY)
- Obesity
- Clomiphene
- Familial adenomatous polyposis
- Vascular disorders such as portal vein agenesis, Budd-Chiari syndrome and hereditary hemorrhagic telangiectasia.
- Oral contraceptive medications
Who is at highest risk?
- The most important risk factor in the development of hepatocellular adenoma is use of oral contraceptive medications.
- Drospirenone and Ethinyl estradiol
- Norethindrone acetate and Ethinyl estradiol
- Norgestimate and Ethinyl estradiol
- Norgestrel and Ethinyl estradiol
- The risk is proportional to:[1]
- Hormonal dose
- Duration of medication
- Other risk factors include:[1]
Risk factors for malignant transformation
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:
- Gender (men)
- Size (> 8 cm)
- Subtype (beta-catenin-activated HCA)
Diagnosis
- If a liver tumor is suspected, your doctor might suggest tests to identify the tumor and its cause. They might also suggest tests to rule out other potential diagnoses.
- An ultrasound is often one of the first steps your doctor will take to help them make a diagnosis. If your doctor finds a large mass through an ultrasound, additional tests might be required to confirm that the mass is a hepatic adenoma.
- Other imaging tests, such as CT scans and MRIs, can be used to learn more about the tumor.
- If the tumor is large, your doctor might also suggest a biopsy. During a biopsy, a small tissue sample is removed from the mass and evaluated under a microscope.
When to seek urgent medical care?
Treatment options
Medical Therapy
- There is no specific medical therapy for the hepatocellular adenoma.[2][3]
- Historically, hepatocellular adenomas were treated with a wait and watch policy, with surgical intervention recommended for larger (>5cm) tumors.
- In asymptomatic female patients suffering from hepatocellular adenomas, the first step is to stop the offending drug (such as OCPs) and check adenoma size on follow-up.
- The wait and watch policy is recommended when hepatocellular adenomas are <5cm or regress (to <5cm) following cessation of offending drug (OCPs) and no further growth is detected.[4]
- An annual follow-up with MRI or ultrasound is scheduled for patients untill menopause.[1][5][6][7][8][9][10]
Surgical Therapy
- Surgery is the treatment of choice for hepatocellular adenoma, as it can achieved in a controlled and safe manner.[11][2][3]
- Elective surgical resection of hepatocellular adenoma is considered for all adenoma lesions >5cm in diameter, lesions that increase in size, lesions with intratumoral hemorrhage and male patients (irrespective of adenoma size).[12][13]
- Liver transplantation may be considered for patients of hepatocellular adenoma associated with glycogen storage disease type 1.[14]
- In adenoma patients who are poor candidates for surgery (centrally located lesions, multiple adenomas, morbid obesity), radiofrequency ablation (RFA) and transcatheter arterial embolization (TAE) may be considered.
- Radiofrequency ablation (RFA) is a minimally invasive technique that can be used for hepatocellular adenomas, hepatocellular carcinoma and colorectal metastases as well.[15]
- Transcatheter arterial embolization (TAE) is used in adenoma patients with hemodynamic instability due to bleeding hypervascular arterial lesions.
Where to find medical care for Hepatocellular adenoma?
Directions to Hospitals Treating Hepatocellular adenoma
Prevention of Hepatocellular adenoma
What to expect (Outlook/Prognosis)?
- The prognosis is usually good for hepatocellular adenoma.
- When diagnosed, the discontinuation of oral contraception or androgen intake leads to regression of hepatocellular adenoma.
- In cases that do not regress after the withdrawal of oral contraception or androgen, surgical treatment is the management of choice.[16]
Possible complications
- When left untreated, hepatic adenomas can rupture spontaneously. This can cause abdominal pain and internal bleeding. A ruptured hepatic adenoma requires immediate medical treatment.
- In rare cases, untreated hepatic adenomas can become cancerous. This is more likely when the tumor is large.
- Several studies suggest that β-catenin activated hepatic adenomas are more likely to become cancerous. Additional research is needed to understand the link between hepatic adenoma types and cancer.
Source
- ↑ 1.0 1.1 1.2 Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ 2.0 2.1 Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G (2005). "Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors". World J Gastroenterol. 11 (36): 5691–5. PMID 16237767.Full text
- ↑ 3.0 3.1 Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC (1996). "Selective management of hepatic adenomas". Am Surg. 62 (10): 825–9. PMID 8813164.
- ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=
ignored (help) - ↑ A. F. Mariani, A. S. Livingstone, R. V. Jr Pereiras, P. E. van Zuiden & E. R. Schiff (1979). "Progressive enlargement of an hepatic cell adenoma". Gastroenterology. 77 (6): 1319–1325. PMID 499719. Unknown parameter
|month=
ignored (help) - ↑ P. H. Andersen & J. T. Packer (1976). "Hepatic adenoma. Observations after estrogen withdrawal". Archives of surgery (Chicago, Ill. : 1960). 111 (8): 898–900. PMID 182106. Unknown parameter
|month=
ignored (help) - ↑ S. Kay (1977). "Nine year follow-up of a case of benign liver cell adenoma related to oral contraceptives". Cancer. 40 (4): 1759–1760. PMID 198104. Unknown parameter
|month=
ignored (help) - ↑ P. Aseni, C. V. Sansalone, C. Sammartino, F. D. Benedetto, G. Carrafiello, A. Giacomoni, C. Osio, M. Vertemati & D. Forti (2001). "Rapid disappearance of hepatic adenoma after contraceptive withdrawal". Journal of clinical gastroenterology. 33 (3): 234–236. PMID 11500616. Unknown parameter
|month=
ignored (help) - ↑ H. Buhler, M. Pirovino, A. Akobiantz, J. Altorfer, M. Weitzel, E. Maranta & M. Schmid (1982). "Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use". Gastroenterology. 82 (4): 775–782. PMID 6277724. Unknown parameter
|month=
ignored (help) - ↑ B. Heeringa & A. Sardi (2001). "Bleeding hepatic adenoma: expectant treatment to limit the extent of liver resection". The American surgeon. 67 (10): 927–929. PMID 11603546. Unknown parameter
|month=
ignored (help) - ↑ Paulette Bioulac-Sage, Herve Laumonier, Gabrielle Couchy, Brigitte Le Bail, Antonio Sa Cunha, Anne Rullier, Christophe Laurent, Jean-Frederic Blanc, Gaelle Cubel, Herve Trillaud, Jessica Zucman-Rossi, Charles Balabaud & Jean Saric (2009). "Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience". Hepatology (Baltimore, Md.). 50 (2): 481–489. doi:10.1002/hep.22995. PMID 19585623. Unknown parameter
|month=
ignored (help) - ↑ T. Terkivatan, J. H. de Wilt, R. A. de Man, R. R. van Rijn, H. W. Tilanus & J. N. IJzermans (2001). "Treatment of ruptured hepatocellular adenoma". The British journal of surgery. 88 (2): 207–209. doi:10.1046/j.1365-2168.2001.01648.x. PMID 11167868. Unknown parameter
|month=
ignored (help) - ↑ J. Belghiti, D. Pateron, Y. Panis, V. Vilgrain, J. F. Flejou, J. P. Benhamou & F. Fekete (1993). "Resection of presumed benign liver tumours". The British journal of surgery. 80 (3): 380–383. PMID 8472159. Unknown parameter
|month=
ignored (help) - ↑ Jan P. Lerut, Olga Ciccarelli, Christine Sempoux, Etienne Danse, Jacques deFlandre, Yves Horsmans, Etienne Sokal & Jean-Bernard Otte (2003). "Glycogenosis storage type I diseases and evolutive adenomatosis: an indication for liver transplantation". Transplant international : official journal of the European Society for Organ Transplantation. 16 (12): 879–884. doi:10.1007/s00147-003-0613-3. PMID 12904843. Unknown parameter
|month=
ignored (help) - ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). "Hepatocellular adenoma: when and how to treat? Update of current evidence". Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=
ignored (help) - ↑ Sung W. Cho, J. Wallis Marsh, Jennifer Steel, Shane E. Holloway, Jason T. Heckman, Erin R. Ochoa, David A. Geller & T. Clark Gamblin (2008). "Surgical management of hepatocellular adenoma: take it or leave it?". Annals of surgical oncology. 15 (10): 2795–2803. doi:10.1245/s10434-008-0090-0. PMID 18696154. Unknown parameter
|month=
ignored (help)
Categories:
- Pages with reference errors
- CS1 maint: PMC format
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Disease
- Types of cancer
- Patient information
- Oncology patient information
- Gastroenterology
- Gastroenterology patient information
- Hepatology
- Up-To-Date
- Oncology
- Medicine
- Surgery